JMP Securities lowered the firm’s price target on Integra LifeSciences to $35 from $40 and keeps an Outperform rating on the shares following the Q2 results. While the firm knew PriMatrix and SurgiMend would remain off the market until manufacturing starts at the new plant in Braintree, the firm did not know that management would also implement a new compliance master plan, which led to some voluntary shipping holds and back orders for certain CSS lines, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- IART Earnings this Week: How Will it Perform?
- Integra LifeSciences price target raised to $32 from $25 at Truist
- Integra LifeSciences to Host Second Quarter 2024 Financial Results Conference Call on July 29, 2024
- Integra LifeSciences Provides Updated Plans for Its Manufacturing Facility in Braintree, Massachusetts
- Integra LifeSciences provides update plans for manufacturing facility in MA